Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

  • Technology appraisal guidance
  • TA428
  • Published: 
  • Last updated: 
Download guidance (PDF)

Update information

September 2017: Reference to a patient access scheme in recommendation 1.1 has been replaced with details of a commercial access agreement. Sections 2 and 5.4 have been updated with the same information.

ISBN: 978-1-4731-2265-9